Roivant Sciences Ltd.

ROIVNASDAQHealthcare● Active

$28.63

+$0.05(+0.16%)

Market Cap$20.6B

P/E Ratio—

52W High$32.793

52W Low$10.705

Avg Volume5.8M

Open$28.52

Beta1.14

Free Cash Flow Financials Revenue

Roivant Sciences Ltd. (ROIV) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ROIV · free cash flow · updated Jun 8, 2026

Core FCF metrics

ROIV · FCF · TTM · margin & CAGR

Free cash flow was −$758.6M for FY2026 (fiscal year ending 2026-03-31), up 10.1% year-over-year

FY2026 Free Cash Flow−$758.6M▲ +10.1% YoY

Trailing 12M (TTM)−$758.6Mtrailing 4 quarters sum

FCF Margin< −999%−$758.6M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ROIV · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2026Latest−$750.3M(8M)−$758.6M▲ +10.1%—

FY2025−$839.5M(5M)−$844.0M▼ 10.1%—

FY2024−$765.3M(1M)−$766.6M▲ +10.4%—

FY2023−$843.4M(13M)−$856.1M▼ 23.1%—

FY2022−$677.7M(17M)−$695.2M▼ 24.6%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ROIV · P/FCF · FCF yield · FCF per share

Roivant Sciences Ltd. (ROIV) reported negative free cash flow of −$0.76B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2026 · 2026-03-31

Cash flow statement summary

ROIV · cash flow statement · operating / investing / financing

For FY2026, Roivant Sciences Ltd. generated −$750.3M in operating cash flow and spent 8M in capital expenditures, yielding −$758.6M in free cash flow.

Operating Activities

−$750.3M

Cash from core business operations

2026-03-31

Investing Activities

−$682.3M

CapEx, acquisitions & investments

2026-03-31

Financing Activities

+$134.2M

Buybacks, dividends & debt

2026-03-31

FCF FormulaOperating CF (−$750.3M) − |CapEx| (8M) = FCF (−$758.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ROIV vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Roivant Sciences Ltd.YOU

ROIV

−$758.6M+10.1%-9183.5%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Roivant Sciences Ltd. (ROIV) reported free cash flow of −$758.6M for FY2026 (fiscal year ending 2026-03-31), up 10.1% year-over-year.

Roivant Sciences Ltd. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 7 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ROIV free cash flow · 8 questions

Roivant Sciences Ltd. free cash flow was −$758.6M for FY2026, up 10.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$758.6M.

ROIV free cash flowROIV FCFROIV FCF 2026ROIV free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Roivant Sciences Ltd. · Roivant Sciences Ltd. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026